Multiplexed ICE COLD-PCR (MX-ICP), Precipio's exclusive technology, amplifies the limited amount of mutant DNA present in plasma to enable accurate liquid biopsies. This means Oncologists can be more confident in their treatment choice for cancer patients.
|Ultra High Sensitive MULTIPLEXED ICE COLD-PCR (MX-ICP)||Accepted Samples|
|Test Code||Test Description||Peripheral Blood||FFPE|
|4002-Q||MX-ICP EGFR- TKI Resistance Analysis: Multiplexed ICE COLD-PCR amplification and sequencing of EGFR exon 20 (T790M & C797S) to detect the development of resistance to EGFR-TKI therapy.|
|4001-Q||MX-ICP EGFR 20 (T790M) Analysis: Multiplexed ICE COLD-PCR amplification and sequencing of EGFR exon 20 T790M to detect the development of resistance to EGFR-TKI therapy.|
|4000-Q||MX-ICP EGFR 20 (C797S) Analysis: Multiplexed ICE COLD-PCR amplification and sequencing of EGFR exon 20 C797S to detect the development of resistance to EGFR-TKI therapy.|
85% of NSCLC EGFR mutations indicate sensitivity to EGFR-Tyrosine Kinase inhibitors (TKI).
For NSCLC treatment, the EGFR T790M mutation is the most common mutation associated with acquired resistance to TKI therapy and has been reported in ~50% of patients with disease progression. ~33% of patients after osimertinib treatment were positive for EGFR C797S mutations.
Patients with any known KRAS mutation should not be treated with either cetuximab or panitumab.
|Specimen Type||Preservative||Volume||Temp||Stability||Turnaround Time|
|Peripheral Blood||EDTA Lavender Top Tube||4 mL||Room Temperature||48-72 hrs||7-10 days|
|Cell Free DNA
|6mL||Room Temperature||15 days||7-10 days|
and 1 H&E
|Room Temperature||N/A||7-10 days|
Muliplexed ICE COLD-PCR (Improved and Complete Enrichment CO-amplification at Lower Denaturation temperature) technology preferentially enriches mutant DNA sequences in an excess of wild-type DNA through selective amplification of the mutant DNA. The result is up to a 500-fold increase in sensitivity in identifying mutations with the most precise sequence alteration detection rates available-down to 0.1%*.